The risk or severity of adverse effects can be increased when Clopidogrel is combined with Balsalazide. SRT501 may increase the anticoagulant activities of Clopidogrel. The serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Tranylcypromine resulting in a loss in efficacy. Dasatinib may increase the anticoagulant activities of Clopidogrel. Clopidogrel may increase the anticoagulant activities of Streptokinase. The risk or severity of adverse effects can be increased when Rifapentine is combined with Clopidogrel. The serum concentration of Amodiaquine can be increased when it is combined with Clopidogrel. Clopidogrel may increase the anticoagulant activities of Tinzaparin. Clopidogrel may increase the anticoagulant activities of Dextran. The risk or severity of adverse effects can be increased when Rifaximin is combined with Clopidogrel. The metabolism of Ketobemidone can be decreased when combined with Clopidogrel. Clopidogrel may increase the anticoagulant activities of Cilostazol. The metabolism of Clopidogrel can be decreased when combined with Dosulepin. The metabolism of Vortioxetine can be decreased when combined with Clopidogrel. The therapeutic efficacy of Clopidogrel can be decreased when used in combination with Pregabalin. The serum concentration of Clopidogrel can be decreased when it is combined with Dabrafenib. Clopidogrel may increase the anticoagulant activities of Edoxaban. The therapeutic efficacy of Clopidogrel can be decreased when used in combination with Darodipine. The serum concentration of Clopidogrel can be increased when it is combined with Peginterferon alfa-2b. The metabolism of Artemether can be decreased when combined with Clopidogrel. Morphine may decrease the antiplatelet activities of Clopidogrel. The metabolism of Mephenytoin can be decreased when combined with Clopidogrel. The therapeutic efficacy of Clopidogrel can be decreased when used in combination with Diltiazem. The metabolism of Mianserin can be decreased when combined with Clopidogrel. The serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Clotrimazole resulting in a loss in efficacy. The metabolism of Tamoxifen can be decreased when combined with Clopidogrel. The serum concentration of Clopidogrel can be increased when it is combined with Mifepristone. Ibudilast may increase the anticoagulant activities of Clopidogrel. Clopidogrel may increase the anticoagulant activities of Phenindione. Clopidogrel may increase the anticoagulant activities of Letaxaban. The metabolism of Enasidenib can be decreased when combined with Clopidogrel. The risk or severity of adverse effects can be increased when Rifabutin is combined with Clopidogrel. The serum concentration of Conivaptan can be increased when it is combined with Clopidogrel. The metabolism of Clopidogrel can be decreased when combined with Midostaurin. The metabolism of Clopidogrel can be increased when combined with Carbamazepine. Omega-3 fatty acids may increase the antiplatelet activities of Clopidogrel. Clopidogrel may increase the anticoagulant activities of Acenocoumarol. The serum concentration of Clopidogrel can be decreased when it is combined with Enzalutamide. Vitamin E may increase the antiplatelet activities of Clopidogrel. The metabolism of Clopidogrel can be decreased when combined with Lovastatin. The serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Modafinil resulting in a loss in efficacy. The metabolism of Clopidogrel can be decreased when combined with Valsartan. Treprostinil may increase the antiplatelet activities of Clopidogrel. The serum concentration of Repaglinide can be increased when it is combined with Clopidogrel. The metabolism of Clopidogrel can be decreased when combined with Saquinavir. The serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Etravirine resulting in a loss in efficacy. Clopidogrel may increase the anticoagulant activities of Enoxaparin. Clopidogrel may increase the anticoagulant activities of Pentaerythritol Tetranitrate. The therapeutic efficacy of Clopidogrel can be decreased when used in combination with Carboxyamidotriazole. The metabolism of Clopidogrel can be decreased when combined with Trimethoprim. The therapeutic efficacy of Clopidogrel can be decreased when used in combination with Clevidipine. The metabolism of Epinastine can be decreased when combined with Clopidogrel. Icosapent ethyl may increase the anticoagulant activities of Clopidogrel. The risk or severity of adverse effects can be increased when Clopidogrel is combined with Nitroaspirin. The therapeutic efficacy of Clopidogrel can be decreased when used in combination with Felodipine. The serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Voriconazole resulting in a loss in efficacy. Clopidogrel may increase the anticoagulant activities of Reviparin. The metabolism of Clopidogrel can be decreased when combined with Sulfisoxazole. The metabolism of Malathion can be decreased when combined with Clopidogrel. The metabolism of Tretinoin can be decreased when combined with Clopidogrel. The metabolism of Promethazine can be decreased when combined with Clopidogrel. The metabolism of Clopidogrel can be decreased when combined with Theophylline. The metabolism of Ospemifene can be decreased when combined with Clopidogrel. The metabolism of Clopidogrel can be decreased when combined with Olaparib. The serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Cholecalciferol resulting in a loss in efficacy. Clopidogrel may increase the anticoagulant activities of Ardeparin. The metabolism of Perphenazine can be decreased when combined with Clopidogrel. The metabolism of Clopidogrel can be decreased when combined with Ropinirole. The therapeutic efficacy of Clopidogrel can be decreased when used in combination with Perhexiline. The therapeutic efficacy of Clopidogrel can be decreased when used in combination with Azelnidipine. The metabolism of Permethrin can be decreased when combined with Clopidogrel. The metabolism of Benzphetamine can be decreased when combined with Clopidogrel. The therapeutic efficacy of Clopidogrel can be decreased when used in combination with Tranilast. The risk or severity of adverse effects can be increased when Clopidogrel is combined with Methyl salicylate. Clopidogrel may increase the anticoagulant activities of Higenamine. The metabolism of Sevoflurane can be decreased when combined with Clopidogrel. The therapeutic efficacy of Clopidogrel can be decreased when used in combination with Barnidipine. The serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Sertraline resulting in a loss in efficacy. The serum concentration of Clopidogrel can be increased when it is combined with Fosaprepitant. The metabolism of clomethiazole can be decreased when combined with Clopidogrel. Clopidogrel may increase the anticoagulant activities of Reteplase. The metabolism of Clopidogrel can be increased when combined with Phenobarbital. The metabolism of Imipramine can be decreased when combined with Clopidogrel. The therapeutic efficacy of Clopidogrel can be decreased when used in combination with Efonidipine. The therapeutic efficacy of Clopidogrel can be decreased when used in combination with Mibefradil. The metabolism of Clopidogrel can be decreased when combined with Topiroxostat. The metabolism of Amitriptyline can be decreased when combined with Clopidogrel. The metabolism of Clopidogrel can be decreased when combined with Venlafaxine. Clopidogrel may increase the anticoagulant activities of Bemiparin. The serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Fluoxetine resulting in a loss in efficacy. The metabolism of Clopidogrel can be decreased when combined with Floxuridine. The serum concentration of Clopidogrel can be increased when it is combined with Palbociclib. The metabolism of Ethylmorphine can be decreased when combined with Clopidogrel. Clopidogrel may increase the anticoagulant activities of Ditazole. The metabolism of Clopidogrel can be increased when combined with Primidone. Clopidogrel may increase the anticoagulant activities of Abciximab. The therapeutic efficacy of Clopidogrel can be decreased when used in combination with Magnesium Sulfate. The therapeutic efficacy of Clopidogrel can be decreased when used in combination with Eperisone. The serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Citalopram resulting in a loss in efficacy. The serum concentration of Clopidogrel can be increased when it is combined with Ranolazine. Relcovaptan may increase the anticoagulant activities of Clopidogrel. The serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Delavirdine resulting in a loss in efficacy. The risk or severity of adverse effects can be increased when Clopidogrel is combined with Deoxycholic Acid. The metabolism of Clopidogrel can be decreased when combined with Doxycycline. The metabolism of Clopidogrel can be decreased when combined with Crisaborole. The metabolism of Diphenhydramine can be decreased when combined with Clopidogrel. Clopidogrel may increase the anticoagulant activities of Protocatechualdehyde. Clopidogrel may increase the anticoagulant activities of Bivalirudin. The metabolism of Clopidogrel can be decreased when combined with Cobicistat. Clopidogrel may increase the anticoagulant activities of Dalteparin. The therapeutic efficacy of Clopidogrel can be decreased when used in combination with Benidipine. The therapeutic efficacy of Clopidogrel can be decreased when used in combination with Nisoldipine. The metabolism of Clopidogrel can be decreased when combined with Dihydroergotamine. The risk or severity of adverse effects can be increased when Clopidogrel is combined with Aminosalicylic Acid. Clopidogrel may increase the anticoagulant activities of Dextran 75. Clopidogrel may increase the anticoagulant activities of Desmoteplase. The therapeutic efficacy of Clopidogrel can be decreased when used in combination with Manidipine. The metabolism of Clopidogrel can be decreased when combined with Sildenafil. The metabolism of Clopidogrel can be decreased when combined with Sulfadiazine. The serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Nelfinavir resulting in a loss in efficacy. Clopidogrel may increase the anticoagulant activities of Dicoumarol. The therapeutic efficacy of Clopidogrel can be decreased when used in combination with Nimodipine. Clopidogrel may increase the anticoagulant activities of Drotrecogin alfa. The serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Rabeprazole resulting in a loss in efficacy. The metabolism of Cisapride can be decreased when combined with Clopidogrel. The risk or severity of adverse effects can be increased when Clopidogrel is combined with Salicylic acid. Clopidogrel may increase the anticoagulant activities of Eplivanserin. The therapeutic efficacy of Clopidogrel can be decreased when used in combination with Nilvadipine. The serum concentration of Clopidogrel can be decreased when it is combined with St. John's Wort. Clopidogrel may increase the anticoagulant activities of Astaxanthin.